Alcidion Group Ltd is a provider of intelligent informatics software. The company builds, sells, delivers, runs, and supports solutions for healthcare provider organizations. It offers solutions such as Miya ED, Miya Patient Flow, Miya Revenue and Reimbursement, Smartpage, and others. Geographically, it derives a majority of its revenue from Australia/New Zealand and also has a presence in the United Kingdom.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The FDA has approved Ciliatech's Investigational Device Exemption application to launch a U.S. feasibility study of the INTERCIL Uveal Spacer in primary open-angle glaucoma. - The study is expected to enroll approximately 30 patients across three U.S. clinical sites, evaluating the device's safety and performance. - INTERCIL is a non-resorbable, 26% hydrophilic acrylic implant placed via an ab externo approach to restore uveoscleral outflow without entering the anterior chamber. - European SAFARI first-in-human data showed stable intraocular pressure control, with 95% of patients below 21 mmHg at 24 months and 90% free of prostaglandin medication.
- Wolfe Research upgraded Abbott Laboratories to Outperform from Peer Perform, setting a $130 target price on the healthcare and diagnostics company. - AbbVie was also upgraded to Outperform from Peer Perform at Wolfe Research, with a $300 target price objective. - The upgrades came as markets rallied broadly after consumer price index data landed in line with expectations at 3.4% year-over-year. - Stryker was cut to Peer Perform from Outperform at Wolfe Research, while Monopar Therapeutics was downgraded to Neutral from Overweight at Cantor Fitzgerald.
- At ASRS 2026 in Montreal, durable treatment strategies for wet AMD dominated research, with gene therapy, intravitreal implant and optogenetic data presented across four days. - Ocular Therapeutix reported phase 3 SOL-1 results showing a single AXPAXLI injection maintained BCVA in 74.1% of patients at Week 36 versus 55.8% with monthly aflibercept. - Nanoscope Therapeutics presented 3-year REMAIN data showing durable BCVA gains of about 3 ETDRS lines with MCO-010 in retinitis pigmentosa, alongside a rolling BLA submission. - Belite Bio's phase 3 DRAGON trial of oral tinlarebant met its primary endpoint with a 36% reduction in retinal lesion growth versus placebo in Stargardt disease.
- RxSight reported preliminary Q2 2026 total revenue of approximately $32–$34 million, including $5–$7 million from its newly announced strategic collaboration with Alcon. - The company sold 24,917 Light Adjustable Lens (LAL) units and placed 11 Light Delivery Devices (LDD) in the quarter, while facing what CEO Ron Kurtz described as "meaningful commercial headwinds." - RxSight unveiled a next-generation Light Adjustable Technology platform featuring new LAL, LAL+, and LAL Toric lenses with improved workflow and fewer post-operative treatments. - Full-year 2026 revenue guidance was revised to $140–$160 million, with product sales lowered to $110–$120 million and gross margin raised to 73%–75%.
- Theialife has appointed Thomas Ruggia as President and CEO to advance its lead candidate ND10, a first-in-class oral therapy for pediatric myopia progression. - ND10 (7-Methylxanthine) is an adenosine A2A receptor antagonist supported by over 20 years of compassionate-use data from more than 1,200 children in Denmark. - Ruggia brings 25+ years of ophthalmology leadership experience from Johnson & Johnson, Alcon, and Samsara Vision, with expertise in late-stage development and commercialization. - The company is preparing to initiate Phase 3 clinical trials for ND10 as it addresses one of the largest unmet needs in ophthalmology.
- Gland Pharma Limited secured FDA approval for its generic version of olopatadine hydrochloride 0.7% ophthalmic solution, equivalent to Alcon's Pataday Once Daily Extra Strength. - The over-the-counter eye drops treat ocular itching associated with allergic conjunctivitis and provide 24-hour relief with once-daily dosing. - This approval marks the second generic version of a Pataday formulation to receive FDA clearance, following Glenmark's approval for the 0.2% concentration in 2025. - The company's shares gained 0.99% following the announcement, reflecting investor confidence in Gland Pharma's expanding ophthalmic portfolio.
- AbbVie is conducting a Phase 2 clinical trial of Icalcaprant, an oral experimental treatment for major depressive disorder, testing two dose levels against placebo over six weeks at 35 North American sites. - The company is simultaneously running a Phase 3 trial of ABBV-444, a new artificial tear formulation for dry eye disease, comparing it directly with REFRESH OPTIVE® Unit Dose over 90 days in approximately 250 patients. - Both trials represent AbbVie's strategic expansion beyond its core immunology and oncology franchises into neuroscience and ophthalmology markets. - Positive results from either program could provide new revenue streams and portfolio diversification for the pharmaceutical company.
- Cosette Pharmaceuticals received FDA approval for the first generic version of CIPRO HC otic suspension in over 27 years, securing 180 days of competitive generic therapy exclusivity. - The generic ciprofloxacin 0.2% HCl and hydrocortisone 1% otic suspension provides a more affordable treatment option for acute otitis externa patients. - This marks Cosette's fourth CGT approval in three years, with the product manufactured at their North Carolina facility targeting a $17.9 million annual market.
- STAAR Surgical shareholders voted against Alcon's amended $1.6 billion acquisition offer at a January 6 stockholder meeting, leading to the termination of the merger agreement. - Alcon had increased its offer to $30.75 per share from the original $28 per share, representing a 74% premium to STAAR's 90-day volume weighted average price. - Broadwood Partners, owning over 30% of STAAR shares, strongly opposed the deal throughout the process, calling it an "absurd sale process plagued by missteps." - Following the rejection, Alcon will refocus on its refractive strategy including the wavelight plus LASIK system and plans 10+ international product launches in 2026.
- Aurion Biotech's Phase 1/2 CLARA trial demonstrated that 65% of patients receiving high-dose AURN001 achieved significant visual acuity improvements compared to 0% in the control group at 12 months. - The regenerative cell therapy showed dose-dependent efficacy with the high-dose group achieving a mean 12.5-letter improvement in visual acuity and 23.2 μm reduction in corneal thickness. - AURN001 demonstrated excellent safety with no graft rejections or treatment-related serious adverse events across all treatment groups in the 97-patient study. - The company plans to advance to a pivotal Phase 3 trial in the first half of 2026, building on the therapy's existing commercial approval in Japan.
